July 21, 2018 – By Lisa Delgado
Analysts expect Stratasys Ltd. (NASDAQ:SSYS) to report $0.02 EPS on August, 8.They anticipate $0.06 EPS change or 75.00% from last quarter’s $0.08 EPS. SSYS’s profit would be $1.07M giving it 265.75 P/E if the $0.02 EPS is correct. The stock increased 1.00% or $0.21 during the last trading session, reaching $21.26. About 441,737 shares traded. Stratasys Ltd. (NASDAQ:SSYS) has declined 32.98% since July 21, 2017 and is downtrending. It has underperformed by 45.55% the S&P500. Some Historical SSYS News: 17/04/2018 – Mission to the Moon: Stratasys Joins Forces with Lockheed Martin and PADT to Engineer Advanced 3D Printed Parts for NASA’s Orion Mission; 19/04/2018 – DJ Stratasys Ltd, Inst Holders, 1Q 2018 (SSYS); 17/05/2018 – Surgeons Use 3D Printing for Two-Year-Old’s Life-Saving Kidney Transplant at Guy’s and St Thomas’ NHS Foundation Trust; 29/05/2018 – STRATASYS REPORTS RESIGNATION OF ILAN LEVIN AS CEO & DIRECTOR; 29/05/2018 – STRATASYS LTD SSYS.O – ELCHANAN (ELAN) JAGLOM, COMPANY’S CURRENT CHAIRMAN OF BOARD, WILL SERVE AS CEO UNTIL A SUCCESSOR IS APPOINTED; 29/05/2018 – STRATASYS NAMES CHAIRMAN ELCHANAN JAGLOM INTERIM CEO; 03/04/2018 – Stratasys Unveils Spin-off Evolve Additive Solutions to Focus on New “STEP” Technology; 05/03/2018 Stratasys Files Annual Report on Form 20-F for the Year Ended December 31, 2017; 17/04/2018 – MakerBot Launches Teacher Certification Program, First Training for 3D Printing Curriculum; 02/05/2018 – Stratasys Sees FY18 Capital Expenditures of $40M-$50M
Atara Biotherapeutics (ATRA) investors sentiment increased to 3.86 in 2018 Q1. It’s up 2.44, from 1.42 in 2017Q4. The ratio increased, as 81 active investment managers opened new and increased positions, while 21 sold and reduced equity positions in Atara Biotherapeutics. The active investment managers in our database now possess: 83.11 million shares, up from 27.87 million shares in 2017Q4. Also, the number of active investment managers holding Atara Biotherapeutics in top ten positions increased from 0 to 2 for an increase of 2. Sold All: 9 Reduced: 12 Increased: 43 New Position: 38.
Among 5 analysts covering Stratasys (NASDAQ:SSYS), 0 have Buy rating, 0 Sell and 5 Hold. Therefore 0 are positive. Stratasys had 7 analyst reports since February 28, 2018 according to SRatingsIntel. The stock has “Hold” rating by Cowen & Co on Wednesday, February 28. The rating was maintained by FBR Capital with “Hold” on Tuesday, May 29. The stock has “Hold” rating by Piper Jaffray on Wednesday, May 2. Piper Jaffray downgraded Stratasys Ltd. (NASDAQ:SSYS) on Wednesday, April 25 to “Hold” rating. The firm has “Hold” rating by Deutsche Bank given on Thursday, May 3. The firm has “Hold” rating by FBR Capital given on Wednesday, February 28. PiperJaffray downgraded the stock to “Neutral” rating in Thursday, April 26 report.
More important recent Stratasys Ltd. (NASDAQ:SSYS) news were published by: Nasdaq.com which released: “Is Stratasys Ltd. a Buy?” on July 20, 2018, also Seekingalpha.com published article titled: “Stratasys: A Struggling 3D Printer”, Seekingalpha.com published: “Tracking Ken Fisher’s Fisher Asset Management Portfolio – Q2 2018 Update” on July 18, 2018. More interesting news about Stratasys Ltd. (NASDAQ:SSYS) was released by: Benzinga.com and their article: “BofA: IT Hardware Stocks Are Losing Appeal To Funds, But Apple Has Further Upside Potential” with publication date: July 06, 2018.
Investors sentiment decreased to 0.86 in 2018 Q1. Its down 0.24, from 1.1 in 2017Q4. It dropped, as 25 investors sold Stratasys Ltd. shares while 39 reduced holdings. 23 funds opened positions while 32 raised stakes. 34.06 million shares or 1.41% less from 34.55 million shares in 2017Q4 were reported. Rhumbline Advisers invested in 47,281 shares or 0% of the stock. Clearbridge Investments Ltd Liability Corporation, New York-based fund reported 100 shares. Perkins Management Incorporated accumulated 13,950 shares or 0.25% of the stock. Hudock Capital Gp Ltd Com has 20 shares for 0% of their portfolio. Bridgeway Capital Mngmt owns 250,000 shares. Voya Inv Management Ltd Limited Liability Company reported 22,009 shares. Da Davidson And holds 62,765 shares or 0.03% of its portfolio. Edge Wealth Mgmt Ltd Liability Corporation reported 300 shares. Royal Bancorporation Of Canada stated it has 0% of its portfolio in Stratasys Ltd. (NASDAQ:SSYS). Ameriprise Fin Inc has 261,385 shares for 0% of their portfolio. D Scott Neal reported 150 shares. Guardian Cap Advisors Ltd Partnership has invested 0.04% of its portfolio in Stratasys Ltd. (NASDAQ:SSYS). Concourse Cap Management Lc invested 0.28% in Stratasys Ltd. (NASDAQ:SSYS). Federated Investors Pa accumulated 17,876 shares or 0% of the stock. 19,905 are held by Canada Pension Plan Invest Board.
Stratasys Ltd. provides three-dimensional printing and additive manufacturing solutions for the creation of parts used in the processes of designing and manufacturing products; and for the direct manufacture of end parts. The company has market cap of $1.14 billion. The Company’s 3D printing systems utilize its patented fused deposition modeling (FDM) and inkjet PolyJet technologies to enable the production of prototypes, tools used for production and manufactured goods directly from 3D CAD files or other 3D content. It currently has negative earnings. The firm offers entry-level desktop 3D printers to systems for rapid prototyping, and production systems for direct digital manufacturing.
Since January 1, 0001, it had 0 buys, and 28 selling transactions for $19.23 million activity.
Redmile Group Llc holds 6.38% of its portfolio in Atara Biotherapeutics, Inc. for 4.24 million shares. Bridger Management Llc owns 2.54 million shares or 6.01% of their US portfolio. Moreover, Baupost Group Llc Ma has 2.35% invested in the company for 6.25 million shares. The New York-based 12 West Capital Management Lp has invested 0.77% in the stock. Artal Group S.A., a Luxembourg-based fund reported 1.25 million shares.
Another recent and important Atara Biotherapeutics, Inc. (NASDAQ:ATRA) news was published by Seekingalpha.com which published an article titled: “Atara Biotherapeutics: 2 New Catalysts To Fuel Further Growth” on June 22, 2018.
Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The company has market cap of $1.72 billion. The Company’s clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. It currently has negative earnings. The firm is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease.
The stock decreased 0.25% or $0.1 during the last trading session, reaching $39.2. About 206,079 shares traded. Atara Biotherapeutics, Inc. (ATRA) has risen 248.61% since July 21, 2017 and is uptrending. It has outperformed by 236.04% the S&P500. Some Historical ATRA News: 08/05/2018 – ATARA BIOTHERAPEUTICS INC – CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF MARCH 31, 2018 TOTALED $407.3 MLN; 01/05/2018 – Atara Biotherapeutics Expands Commercial Leadership Team with the Appointment of Manuela Maronati as General Manager, Europe; 08/05/2018 – Atara Biotherapeutics: Cash, Cash Equivalents and Short-Term Investments $407.3 Million as of March 31; 26/03/2018 – Atara Bio Presenting at Conference Tomorrow; 17/05/2018 – ATARA REPORTS DATA FROM LONG-TERM TAB-CEL PHASE 2; 01/05/2018 – Atara Biotherapeutics Expands Comml Leadership Team With the Appointment of Manuela Maronati as General Manager, Europe; 26/04/2018 – Atara Bio Closes Above 50-Day Moving Average: Technicals; 08/05/2018 – Atara Bio Closes Below 50-Day Moving Average: Technicals; 08/05/2018 – Atara Biotherapeutics 1Q Loss $41.4M; 14/05/2018 – T Rowe Price Associates Buys New 3.9% Position in Atara Bio
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.